
Bavarian Nordic has struck a new, five-year deal with the US government. The aim of the development contract is to examine if the Danish biotech company’s vaccine technology can be used within other disease areas.
More specifically, the new contract means that Bavarian Nordic over the following years will attempt to develop a combined vaccine against smallpox and Marburg virus – a highly contagious and deadly virus of the Ebola family. The two viruses are both believed to pose a potential bio-terror threat.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app